menu
    • menu
    [{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Neuraxpharm"}]

    Find Clinical Drug Pipeline Developments & Deals for Levomepromazine Maleate

    Menu

    Levomepromazine Maleate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi

                            Details : The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal,...

                            Brand Name : Nozinan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 01, 2023

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm to Increase Branded Business Through Upcoming Acquisition of Established Products from Sanofi

                            Details : Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of se...

                            Brand Name : Nozinan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2022

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth